TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding

TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding

Objective: Metabolic Syndrome, which can be induced or exacerbated by current antipsychotic drugs (APDs), is highly prevalent in schizophrenia patients. Recent preclinical and clinical evidence suggest that agonists at trace amine-associated receptor 1 (TAAR1) have potential as a new treatment optio...

Full description

Bibliographic Details
Main Authors: Nina Dedic, Lien Wang, Eva Hajos-Korcsok, Jacob Hecksher-Sørensen, Urmas Roostalu, Steven P. Vickers, Serena Wu, Christoph Anacker, Colleen Synan, Philip G. Jones, Snezana Milanovic, Seth C. Hopkins, Linda J. Bristow, Kenneth S. Koblan
Format: Article
Language:English
Published: Elsevier 2024-02-01
Series:Molecular Metabolism
Subjects:
Trace amine-associated receptor 1 (TAAR1)
Obesity
Antipsychotics
c-fos imaging
Homeostatic and hedonic feeding circuits
Online Access:http://www.sciencedirect.com/science/article/pii/S2212877824000140

Internet

http://www.sciencedirect.com/science/article/pii/S2212877824000140

Similar Items